| Literature DB >> 35165516 |
Peng Liu1, Yingxin Zhang2, Yujie Ma3, Shuang Tan3, Bingyi Ren3, Shitao Liu3, HuanYan Dai3, Zhimin Xu3.
Abstract
In the maxillofacial area, soft and hard tissue abnormalities are caused by trauma, tumors, infection, and other causes that expose the maxillofacial region to the surface of the human body. Patients' normal physiological function and appearance are interfered with, and their mental health is adversely impacted, reducing their overall life quality. The pursuit of appropriate medical treatments to correct these abnormalities is thus vital. Autologous stem cell regeneration technology mainly focused on tissues has lately emerged as a significant problem in the medical community. Because of the capacity of dental pulp stem cells (DPSCs) to self-renew, the use of DPSCs from the human pulp tissues of deciduous teeth or permanent teeth has gained popularity among scientists as a stem cell-based therapy option. Aside from that, they are simple to extract and have minimal immunogenicity. As a result, bone tissue engineering may be a critical component in treating maxillofacial and periodontal bone abnormalities. DPSCs activity in maxillofacial and periodontal tissue-engineered bone tissue was investigated in this research. © The author(s).Entities:
Keywords: Dental pulp stem cells; osteogenic; periodontal disease; tissue-engineered
Mesh:
Year: 2022 PMID: 35165516 PMCID: PMC8795794 DOI: 10.7150/ijms.68494
Source DB: PubMed Journal: Int J Med Sci ISSN: 1449-1907 Impact factor: 3.738
Regulation of microRNAs in the differentiation of DPSCs.
| DPSCs | miRNA | Mechanisms | References |
|---|---|---|---|
|
| Inhibit Wnt1 signaling pathways |
| |
| MiR-140-5P | Inhibit TLR4 |
| |
| MiR-143-3P | Inhibit RANK |
| |
| MiR-125a-3P | Promote Fyn |
| |
|
| MiR-143 | Inhibit NF-κB via targeting TNF-α |
|
| MiR-146a-5P | Regulate STRO-1+ through NOTCH1 signaling pathways |
| |
| MiR-496 | Inhibit CirRNA12453/β-Catenin signaling pathways |
| |
|
| MiR215/miRNA219a-1-3P | Downregulate HspB8 |
|
| MiR411 | Inhibit HIF-1α and promote autophagy |
| |
| MiR-140-5p | Inhibit Wnt1 signaling pathways |
| |
|
| MiR-454 | Inhibit ephrin receptor B4 promotes the proliferation and invasion of trophoblast cells |
|
Figure 1Potential mechanism of DPSCs in neurological diseases: In the therapy of neurologic illness, DPSCs may be classified into three types of mechanisms: 1) improving brain function via the secretory route; 2) differentiation of new dopaminergic neuron (like) cells; and 3) immune control, which reduces the inflammatory response. Note: Glial cell-derived neurotrophic factor (GDNF) and the and brain-derived neurotrophic factor (BDNF)
Figure 2Differentiation and tissue engineering application of DPSCs cells: Adult bone remodelling is continuously remodelled using osteoclast, osteoblasts, and simultaneous osteoclasts. Stem cells and progenitor cells located in the endometrium and periosteum have limited ability to regenerate and need surgical intervention. The use of biomaterials or bone grafting that mimics bone structure is an essential way to solve bone loss. DPSCs, after differentiation, show the same protein components in mineralized tissues such as osteocalcin, alkaline phosphatase, and osteopontin so that DPSCs can be an excellent source of regenerative osteoblasts and chondroblasts for alveolar and maxillofacial bone. DPSCs originated from nerve ridges and migrated and differentiated to participate in morphogenesis. Therefore, DPSCs have been more widely used in surgical repair and regeneration, resulting in cranial and facial structures, including muscles, ligaments, cartilage, bones, periodontal membranes, and teeth. The expression of these osteogenic markers is related to osteogenic and odontogenic induction drugs. DPSCs can differentiate into functional osteoclasts in vitro, and they have also been found to produce an extracellular mineralized matrix.